Controversies Surrounding Androgen Deprivation for Prostate Cancer

Stephen G. Patterson, MD, Lodovico Balducci, MD, Julio M. Pow-Sang, MD


Cancer Control. 2002;9(4) 

In This Article


Orchiectomy, estrogen agonists, and LHRH analogs produce equivalent clinical responses in advanced prostate cancer. Castration remains the frontline treatment for metastatic prostate cancer. Patients who have undergone definitive local treatment for prostate cancer but have a rising PSA are candidates for initiation of hormonal therapy. For the majority of men with a standard risk of recurrent disease, early hormone treatment should be performed only in the sitting of a randomized clinical trial. MAB does not appear to be significantly more effective than single-agent LHRH analog. Prescription of an antiandrogen during the first month of treatment with an LHRH analog should be considered, but prolonged MAB beyond 1 month is not superior to LHRH analog monotherapy. Castration produces detrimental effects on the musculoskeletal, endocrine, cardiovascular systems, libido, and potency. Intermittent hormonal therapy may delay progression to the hormone refractory state and lengthen survival.

This article was originally certified for CME credit. For accreditation details, contact the publisher.
H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Telephone: (813) 632-1349. Fax: (813) 903-4950. Email: Cancer Control is included in Index Medicus/MEDLINE and EMBASE/Excerpta Medica.)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education, the University of South Florida College of Medicine must insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational activities. Faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and (2) with any commercial supporters of the activity. (Significant financial interest or other relationship can include such things as grants or research support, employee, consultant, major stock holder, member of speaker's bureau, etc.). The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.